Copyright
©The Author(s) 2022.
World J Diabetes. Jan 15, 2022; 13(1): 5-26
Published online Jan 15, 2022. doi: 10.4239/wjd.v13.i1.5
Published online Jan 15, 2022. doi: 10.4239/wjd.v13.i1.5
Ref. | Sample size | Country | PCOS criteria | T2D criteria | Age (yr) | BMI (kg/m2)
| IFG (%) | IGT (%) | T2D (%) |
Rajkhowa et al[142], 1996 | 90 | UK | NIH | WHO | 26 (15-39) | 31.6 (18-48) | ? | 9 | 2 |
Legro et al[61], 1999 | 254 | USA | NIH | WHO | 14-44 | 32 ± 3 | ? | 31 | 7.5 |
Ehrmann et al[62], 1999 | 122 | USA | NIH | ADA | 25 ± 0.7 (13-40) | 30-43 | 9 | 35 | 10 |
Gambineri et al[3], 2004 | 121 | Italy | Rotterdam | WHO | 14-37 | 20-38 | ? | 15.7 | 2.5 |
Legro et al[143], 2005 | 71 | USA | NIH | ADA | 30 ± 6 | 29 ± 6.4 | ? | 25 | 10 |
Chen et al[144], 2006 | 102 | China | Rotterdam | WHO | 24.2 ± 6 | 21.7 ± 4 | ? | 20.5 | 1.9 |
Mohlig et al[64], 2006 | 264 | Germany | NIH | WHO | 28 ± 0.4 | 30 ± 0.4 | ? | 14.3 | 1.5 |
Vrbikova et al[145], 2007 | 244 | Czech Republic | Rotterdam | ADA | 27 ± 7.5 | 27 ± 6.9 | 12.3 | 9.4 | 1.6 |
Gagnon et al[146], 2007 | 105 | Canada | NIH | ADA | 28.3 (14-47) | 35.5 (19-54) | ? | 23 | 5 |
Dabadghao et al[63], 2007 | 372 | Australia | Rotterdam | ADA | 30 ± 5 (15-62) | 35 ± 8 | 3 | 15.6 | 4 |
Espinos-Gomez et al[147], 2008 | 102 | Spain | NIH | WHO | 26 ± 6 | 30.2 ± 8 | ? | 10.7 | 7.7 |
Cheung et al[148], 2008 | 295 | China | Rotterdam | ADA | 30 ± 6 | 25 ± 5.9 | 9.2 | 10.5 | 7.5 |
Bhattacharya et al[149], 2009 | 264 | India | Rotterdam | WHO | 24 ± 4 | 27 ± 4.5 | ? | 14.4 | |
Seneviratne et al[15], 2009 | 168 | Sri Lanka | Rotterdam | WHO | 29 ± 4 (20–40) | 25.92 (16-39) | ? | 23.2 | 10.1 |
Lee et al[50], 2009 | 194 | Korea | Rotterdam | ADA | 27 ± 5 | 24 ± 4 | 17 | 1 | |
Wei et al[51], 2009 | 356 | China | Rotterdam | WHO | 32 ± 4 (19-44) | 22 ± 4.2 | ? | 7.6 | 3,1 |
Zhao et al[150], 2010 | 818 | China | Rotterdam | ADA | 25 ± 5 | ? | 8.5 | 35.4 | 4 |
Stovall et al[151], 2011 | 78 | USA | NIH | ADA | 26 ± 6.4 | 29 ± 6 (18-43) | 2 | 14 | ? |
Celik et al[66], 2013 | 252 | Turkey | Rotterdam | ADA | 24 ± 5 | 26 ± 5.7 | ? | 14.3 | 2 |
Veltman-Verhulst et al[21], 2013 | 226 | Netherlands | Rotterdam | ADA | 29.6 ± 4 | 27 ± 6.7 | 21 | 4 | 3.5 |
Lerchbaum et al[152], 2014 | 714 | Austria | Rotterdam | ADA | 27 (23-32) | 24.2 (21-30) | 12.8 | 1.5 | |
Vrbikova et al[145], 2014 | 330 | Czech Republic | Rotterdam | ADA | 27.8 ± 7 | 27.6 ± 6 | 12 | 8.8 | 3 |
Amato et al[22], 2015 | 241 | Italy | Rotterdam | WHO | 24 ± 6 (14-43) | 30 ± 6 (18-50) | 11.6 | 5.4 | 1.7 |
Ganie et al[14], 2015 | 2014 | India | Rotterdam | ADA | 23 ± 5.4 | 25 ± 4.4 | 14.5 | 5.9 | 6.3 |
Gracelyn et al[153], 2015 | 200 | India | Rotterdam | ADA | 16-40 | ? | ? | 14.5 | 1.5 |
Li et al[154], 2016 | 2436 | China | Rotterdam | ADA | 27 | 21.56 | 13.5 | 19.8 | 3.9 |
Ollila et al[127], 2017 | 265 | Finland | Rotterdam | WHO | 46 | 28.6 ± 6 | ? | ? | 12.4 |
Pelanis et al[13], 2017 | 876 | Sweden | Rotterdam | ADA | 29 (25-34) | 28 (23-33) | 11 | 12 | 3 |
Zhang et al[19], 2018 | 378 | China | Rotterdam | IDF | 27 ± 4.4 | 30 ± 4.3 | 31.5 | 8.7 | |
Ortiz-Flores et al[155], 2019 | 400 | Spain | Rotterdam | WHO | 26 (14-49) | 28.6 (22-34) | 14 | 14.5 | 2.5 |
- Citation: Livadas S, Anagnostis P, Bosdou JK, Bantouna D, Paparodis R. Polycystic ovary syndrome and type 2 diabetes mellitus: A state-of-the-art review. World J Diabetes 2022; 13(1): 5-26
- URL: https://www.wjgnet.com/1948-9358/full/v13/i1/5.htm
- DOI: https://dx.doi.org/10.4239/wjd.v13.i1.5